辅料聚维酮K30对缬沙坦胶囊质量控制的影响

目的： 对缬沙坦胶囊有关物质检查中一未知物质（相对于缬沙坦峰保留时间的0.14倍）进行来源与结构确证，探讨该未知物质对缬沙坦胶囊质量的影响，为质量标准的修订提供依据。 方法： 有关物质检查采用Inertsil ODS-4色谱柱（250 mm×4.6 mm，5 μm），以乙腈-水-冰醋酸（500：500：1）为流动相，流速1.0 mL·min^-1，检测波长225 nm。对检出的该未知物质，采用UPLC-MS、IR、¹H-NMR及MALDI-TOF-MS等技术确证其来源与结构。 结果： 通过以上检测技术的相互佐证，证实其为辅料聚维酮K30（PVP K30）。 结论： 辅料PVP K30峰不应计入有关物质，应在质量标准中增加扣除辅料峰的说明，以消除其对有关物质检查结果判定的影响。

Objective: To confirm the origin and structure of the unknown substance,eluted at 0.14 fold of the relative retention time of valsartan peak (RRT=0.14),which was detected in related substances test of valsartan capsules;to explore the influence of the unknown material on the quality of valsartan capsules,and to provide basis for the revision of the quality standards. Methods: The analysis was carried out on an Inertsil ODS-4 column(250 mm×4.6 mm,5μm)with a mobile phase of acetonitrile-water-glacial acetic acid(500: 500: 1)at a flow rate of 1 mL·min^-1.The detective wavelength was set at 225 nm.UPLC-MS,IR,¹H-NMR and MALDI-TOF-MS techniques were applied to confirm the origin and structure of the unknown substance. Results: The unknown substance was confirmed to be the excipient povidone K30(PVP K30). Conclusion: The excipient PVP K30 peak is not to be counted as the related substance of valsartan capsules,and it should be specified to deduct the excipient peak in ChP 2010 to eliminate the influence on the result of determination.

[1] ChP 2010.VolⅡ(中国药典2010年版.二部)[S].2010:1136
[2] DENG Ji(邓骥),LIU Jun(刘军),YE Lin(叶琳),et al.Clinical application of valsartan(缬沙坦在临床中的应用)[J].J Chin Hosp Pharm(中国医院药学杂志),2006,26(8):1012
[3] GONG Hui(龚辉),ZHANG Xiang-xian(张象贤),WANG Ya-fen(王亚芬).Efficacy of valartan on essential hypertension and its influence on endothelial function of brachial artery(缬沙坦对高血压病的疗效及其对肱动脉内皮功能的影响)[J].Chin J New Drug Clin Rem(中国新药与临床杂志),2004,23(10):661
[4] ZHANG Liang (张良),WANG Yan-wen (王燕雯).Development of capsules from natural plan polymers(天然植物高分子药用胶囊的研究与发展)[J].Acta Polymer Sin(高分子学报),2013,1(1):1
[5] ZHANG Dong-mei(张冬梅),SONG Shao-jing(宋韶锦),LIU Bing(刘冰).The impact of excipients aspartame on the drug quality control of glipizide dispersible tablets(药用辅料阿司帕坦对格列吡嗪分散片质量控制的影响)[J].China Pharm(中国药业),2005,14(2):44
[6] ZHENG Jin-qi(郑金琪),ZHENG Guo-gang(郑国钢),LI Hui-lin(李会林),et al.Detemination of content and the related substances of simvastatin tablets by HPLC(梯度洗脱HPLC测定辛伐他汀片的含量和有关物质)[J].Chin Pharm J(中国药学杂志),2010,45(9):702
[7] ZHENG Jin-qi(郑金琪),YU Xiong-jie(俞雄杰),ZHENG Guo-gang(郑国钢),et al.HPLC determination of content and the related substances of simvastatin pills(HPLC法测定辛伐他汀滴丸的含量和有关物质)[J].Drug Stand China(中国药品标准)2012,13(6):418
[8] JIA Fei(贾飞),LI Yu(李珏),ZHU Pei-xi(朱培曦).Comparison and discussion of RP-HPLC analysis for related substances in simvastatin tablets(辛伐他汀片有关物质测定方法的筛选与探讨)[J].Chin J Pharm Anal(药物分析杂志),2012,32(10):1826
[9] ZHANG Chi(张弛),ZHU jia-liang(朱嘉亮).Method and strategy of the national drug quality study(我国药品质量分析研究的方法和策略)[J].Chin Pharm Aff(中国药事),2011,25(1):63
[10] USP 35-NF 30[S].2012:4997
[11] EP 7.0[S].2010:3190
[12] JP 16[S].2011:2490